

PAR/CS/NSE/2025-26/27

To,

The Manager

**National Stock Exchange of India Limited**

Exchange Plaza, C-1, Block-G,

Bandra Kurla Complex, Bandra (E),

Mumbai- 400 051

Maharashtra

**Date: 16/09/2025**

**Subject: Disclosure under Regulation 30(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Clause 20 of Para A of Part A of Schedule III**

**Symbol - PAR, ISIN: INE04LG01015**

Dear Sir/Madam,

Pursuant to regulation 30(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (LODR Regulations) read with clause 20 of Para A of Part A of Schedule III of the LODR Regulations, the details of Ex-Parte Interim Order passed by SEBI Official with respect to slump sale are enclosed herewith as Annexure-A.

You are requested to kindly take note on your record.

Yours Faithfully

**For PAR DRUGS AND CHEMICALS LIMITED**



\_\_\_\_\_  
(Sanket B. Trivedi)

**Company Secretary & Compliance Officer**

**Annexure-A**

<b>Name of the authority</b>	Mr. Kamlesh Chandra Varshney Whole Time Member Securities And Exchange Board Of India
<b>Nature and details of the action(s) taken or order(s) passed.</b>	<p>The Securities and Exchange Board of India (SEBI), through an Ex-Parte Interim Order bearing Order No. WTM/KV/CFID/CFID-SEC4/31660/2025-26 dated September 15, 2025, <b>has issued the following directions</b> to Par Drugs and Chemicals Limited ("PDCL" or "the Company") and the buyer, Phal-Jig Fine Chemicals Private Limited ("PJFCPL"), in relation to the proposed Business Transfer Agreement ("BTA") with respect to slump sale transaction:</p> <ol style="list-style-type: none"><li>I. PDCL is restrained from effecting the transactions agreed upon in the BTA dated February 14, 2025 for Slump Sale of its business undertaking to PJFCPL.</li><li>II. The stock exchange (NSE) is directed to appoint a registered valuer to independently carry-out the valuation of the business undertaking proposed to be transferred through the BTA following appropriate valuation methodology as per recognised valuation standards. The registered valuer shall submit a report to NSE within three months from the date of this Order. Further, a fairness opinion shall also be obtained by Stock Exchange (NSE) from a merchant banker regarding the aforesaid valuation within one month from the date of submission of valuation report.</li><li>III. PDCL, its management and all the signatories to the BTA dated February 14, 2025 are directed to cease and desist from entering into any transaction which may directly or indirectly result in alienation of any assets forming subject matter of the BTA until further directions in this matter and they shall extend necessary cooperation to the valuer appointed and to furnish all information/documents sought from them from time to time.</li><li>IV. The Stock Exchange (NSE) is directed to submit the valuation report, fairness opinion along with its recommendation within 15 days from the date of receipt of fairness opinion.</li></ol> <p>The detailed order can be access from the SEBI official website at <a href="https://www.sebi.gov.in/index.html">https://www.sebi.gov.in/index.html</a></p>



<b>Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority;</b>	The Managing Director of the Company has received order through phone on Monday, September 15, 2025 at 08:00 PM. The formal communication of the order has not yet been received by any means.
<b>Details of the violation(s)/ contravention(s) committed or alleged to be committed;</b>	SEBI passed the Ex-Parte Interim Order and give directions as mentioned above.  The detailed order can be access at <a href="https://www.sebi.gov.in/sebi_data/attachdocs/sep-2025/interim_order_pdcl.pdf">https://www.sebi.gov.in/sebi_data/attachdocs/sep-2025/interim_order_pdcl.pdf</a>
<b>Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible.</b>	No any impact on financial, operation or other activities of the listed entity in monetary terms as on date.

